Aridis focuses on anti-infective alternatives to conventional antibiotics


April 9th, 2015.  Aridis Pharmaceuticals Adds Craig Gibbs, Ph.D., MBA, to Board of Directors.  (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

March 26th, 2015.  Aridis Pharmaceuticals Commences Phase 1 Clinical Study of Aerucin™ Monoclonal Antibody for Acute Pneumonia. (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

March 23rd, 2015.  Aridis Pharmaceuticals Appoints Paul-Andre de Lame, M.D., as Chief Medical Officer.  (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

January 6th, 2015.  Aridis Pharmaceuticals to Present at Biotech Showcase 2015.  (More)


News


>> More News


Mining the human immune response for rare monoclonal antibodies to fight infections